Extreme Prostate‐Specific Antigen Response to Infusional 5‐Flourouracil in Castrate‐Resistant Prostate Cancer

AbstractProstate cancer that has progressed after androgen deprivation, abiraterone, and taxane therapy is challenging to treat successfully. Herein we report a dramatic response to continuous‐infusion 5‐fluorouracil (5‐FU) at a dose of 200 mg/m2 in a patient with rapidly progressive, heavily pretreated, metastatic castrate‐resistant prostate cancer. Baseline prostate‐specific antigen values declined from 1,890 ng/mL to <1 ng/mL after 5‐FU therapy. We hypothesized that prostate‐specific membrane antigen overexpression may result in cancer cells uniquely susceptible to antifolate therapies.

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2FIiwdn